揭示HPV和泛癌之间的关联:双向的双样本孟德尔随机化研究
Jianxuan Sun1, Jiacheng Xiang1, Ye An1
1Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, China.
Cancers
|November 14, 2023
概括
人类乳头瘤病毒 (HPV) 类型16和18显示与各种癌症的因果关系. HPV16是膀,结肠直肠和乳腺癌的风险,而HPV18与前列腺,卵巢,肺和乳腺癌有关.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 遗传学 是一个遗传学.
背景情况:
- 越来越多的研究将人类乳头瘤病毒 (HPV) 感染与各种癌症联系起来.
- 现有证据主要来源于回顾性研究,限制因果推断.
- 门德尔随机化 (MR) 提供了一个强大的方法来调查因果关系,克服观察性研究的局限性.
研究的目的:
- 使用双向双样本孟德尔随机化 (MR) 设计,确定特定的人类乳头瘤病毒 (HPV) 类型和12种特定部位癌症之间的因果关系.
- 探索HPV在癌症发展中的潜在作用,超出宫癌.
- 为了研究HPV对瘤免疫微环境的影响,在选择的癌症.
主要方法:
- 采用双向两样 MR 设计,利用全基因组关联研究 (GWAS) 的单核酸多态 (SNP) 作为 HPV 暴露的工具变量.
- 进行了敏感性分析,包括MR-Egger的拦截,MR-PRESSO,Cochran的Q测试,以及留出一个的分析,以确保结果的有效性.
- 在头部和部状细胞癌 (HNSCC),口腔状细胞癌 (OPSCC) 和状状细胞癌 (VSCC) 中使用HPVTIMER进行了免疫透分析,以评估瘤免疫微环境.
主要成果:
- 确定HPV16是膀,结直肠和乳腺癌的危险因素.
- 鉴定出HPV18是前列腺癌,卵巢癌,肺癌和乳腺癌的危险因素.
- HPV16显示出对前列腺癌,门癌,肺癌和口腔癌的潜在保护作用,而HPV18显示出对阴道癌的类似作用.
结论:
- 感染HPV可能会影响瘤免疫微环境,潜在地抑制某些癌症的发展.
- 这些发现为癌症发展机制提供了新的视角.
- 需要进一步的研究来验证这些因果关系,并探索潜在的生物学途径.
更多相关视频
06:57Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
10.4K
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
12.3K
相关概念视频
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
Single Nucleotide Polymorphisms-SNPs
15.2K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.2K
Genome-wide Association Studies-GWAS
13.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.5K
Mismatch Repair
4.9K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.9K
Hazard Ratio
136
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
136
Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
